Michael Venuti - Infinity Pharmaceuticals Independent Director
| INFIDelisted Stock | USD 0.04 0.03 42.86% |
Director
Dr. Michael C. Venuti, Ph.D., is Independent Director of Infinity Pharmaceuticals Inc. Dr. Venuti served as the Chief Scientific Officer of NeuroTherapeutics Pharma, Inc., a privately held biopharmaceutical company from July 2011 to March 2013. Prior to NeuroTherapeutics, Dr. Venuti served as President, Chief Executive Officer and a director of iPierian, Inc., a privately held biopharmaceutical company, between July 2010 and April 2011 after joining iPierian as President and Chief Scientific Officer in February 2010. Dr. Venuti was Chief Executive Officer and Director of BioSeek, Inc., a privately held drug discovery company, from November 2007 to February 2010. Prior to that, Dr. Venuti was an Operating Manager at TPG Growth Biotech Ventures, a private equity firm, from January through June 2007. Dr. Venuti served as the Acting Chief Executive Officer of our predecessor company prior to its merger with Infinity Discovery Inc. in September 2006, and as its Chief Scientific Officer from April 2005 since 2006.
| Age | 60 |
| Tenure | 18 years |
| Professional Marks | Ph.D |
| Phone | 617 453 1000 |
| Web | https://www.infi.com |
Infinity Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.607) % which means that it has lost $0.607 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (35.2135) %, meaning that it created substantial loss on money invested by shareholders. Infinity Pharmaceuticals' management efficiency ratios could be used to measure how well Infinity Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 917 K in liabilities with Debt to Equity (D/E) ratio of 0.13, which may suggest the company is not taking enough advantage from borrowing. Infinity Pharmaceuticals has a current ratio of 4.08, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Infinity Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Infinity Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Infinity Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Infinity to invest in growth at high rates of return. When we think about Infinity Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Joseph Schepers | Chimerix | 58 | |
| Timothy Shannon | CytomX Therapeutics | 56 | |
| Charles Fuchs | CytomX Therapeutics | 57 | |
| Ted Wang | TRACON Pharmaceuticals | 50 | |
| Geoffrey Swier | Instil Bio | N/A | |
| James Niedel | Chimerix | 72 | |
| Gaggar | Instil Bio | 85 | |
| Robert Meyer | Chimerix | N/A | |
| Richard DiMarchi | Assembly Biosciences | 64 | |
| Susan Mahony | Assembly Biosciences | 52 | |
| Aloke Banerjee | Instil Bio | 61 | |
| Anthony Altig | Assembly Biosciences | 61 | |
| Edward Greissing | Chimerix | N/A | |
| James Daly | Chimerix | 56 | |
| Patrick Machado | Chimerix | 54 | |
| Lisa Ricciardi | Chimerix | 57 | |
| Ronald Renaud | Chimerix | 48 | |
| Roger Loeb | Instil Bio | N/A | |
| Mark Auerbach | Assembly Biosciences | 78 | |
| George Rohlinger | Instil Bio | N/A | |
| Paul Newfield | Instil Bio | N/A | |
Management Performance
| Return On Equity | -35.21 | |||
| Return On Asset | -0.61 |
Infinity Pharmaceuticals Leadership Team
Elected by the shareholders, the Infinity Pharmaceuticals' board of directors comprises two types of representatives: Infinity Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Infinity. The board's role is to monitor Infinity Pharmaceuticals' management team and ensure that shareholders' interests are well served. Infinity Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Infinity Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph Pearlberg, Vice President - Clinical Development | ||
| Melissa Hackel, Vice President - Finance | ||
| William Bertrand, Executive Vice President General Counsel | ||
| Vito Palombella, Chief Scientific Officer and Executive VP | ||
| Jeffrey Berkowitz, Independent Director | ||
| Seth JD, Chief VP | ||
| Lawrence Bloch, CFO, Executive Vice President Chief Business Officer | ||
| Norman Selby, Lead Outside Independent Director | ||
| Jose Baselga, Independent Director | ||
| Samuel Agresta, Chief Medical Officer | ||
| Michael Venuti, Independent Director | ||
| Stephane Peluso, Chief Officer | ||
| MD Ilaria, Chief Officer | ||
| Jayne Kauffman, Sr Coordinator | ||
| Michael Kauffman, Independent Director | ||
| Eric Lander, Independent Director | ||
| David Beier, Independent Director | ||
| Julian Adams, President of RandD | ||
| Anthony Evnin, Independent Director | ||
| Gwendolyn Fyfe, Independent Director | ||
| Sujay Kango, Executive Vice President Chief Commercial Officer | ||
| Ian Smith, Independent Director | ||
| Adelene Perkins, Chairman of The Board, CEO and Pres | ||
| MD JD, Pres Treasurer |
Infinity Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Infinity Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -35.21 | |||
| Return On Asset | -0.61 | |||
| Operating Margin | (15.70) % | |||
| Current Valuation | (9.46 M) | |||
| Shares Outstanding | 90.76 M | |||
| Shares Owned By Insiders | 2.36 % | |||
| Shares Owned By Institutions | 23.48 % | |||
| Number Of Shares Shorted | 2.21 M | |||
| Price To Earning | (1.63) X | |||
| Price To Book | 8.03 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Infinity Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Infinity Pharmaceuticals' short interest history, or implied volatility extrapolated from Infinity Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the Infinity Pharmaceuticals information on this page should be used as a complementary analysis to other Infinity Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in Infinity Stock
If you are still planning to invest in Infinity Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Infinity Pharmaceuticals' history and understand the potential risks before investing.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |